Skip to content
10-Q

Quarterly Report

Matinas BioPharma Holdings, Inc. MTNB

0001493152-26-022010

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 6.41M sh
Shares Diluted Q1 2026 · Mar 31, 2026 6.41M sh
Shares Diluted Q1 2026 · Mar 31, 2025 5.09M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$1.6M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.01M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $2.4M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $6.92M
Cash And Equivalents Q1 2026 · Dec 31, 2024 $7.28M
Stockholders Equity Q1 2026 · Mar 31, 2026 $3.02M
Stockholders Equity Q1 2026 · Dec 31, 2025 $4.83M
Stockholders Equity Q1 2026 · Mar 31, 2025 $6.27M
Stockholders Equity Q1 2026 · Dec 31, 2024 $7.59M
Current Liabilities Q1 2026 · Mar 31, 2026 $2.13M
Current Liabilities Q1 2026 · Dec 31, 2025 $1.46M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.85M
Total Liabilities Q1 2026 · Dec 31, 2025 $2.38M
Current Assets Q1 2026 · Mar 31, 2026 $2.82M
Current Assets Q1 2026 · Dec 31, 2025 $4.08M
Total Assets Q1 2026 · Mar 31, 2026 $5.87M
Total Assets Q1 2026 · Dec 31, 2025 $7.21M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.30
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.33
Eps Basic Q1 2026 · Mar 31, 2026 −$0.30
Eps Basic Q1 2026 · Mar 31, 2025 −$0.33
Sga Expense Q1 2026 · Mar 31, 2026 $1.94M
Sga Expense Q1 2026 · Mar 31, 2025 $1.86M
Net Income Q1 2026 · Mar 31, 2026 −$1.92M
Net Income Q1 2026 · Mar 31, 2025 −$1.66M
Operating Income Q1 2026 · Mar 31, 2026 −$1.94M
Operating Income Q1 2026 · Mar 31, 2025 −$1.95M
Rd Expense Q1 2026 · Mar 31, 2025 $85K